Qualigen Therapeutics (QLGN) announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock, effective at 12:01 a.m. Eastern time on November 5, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol “QLGN.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN:
- Qualigen Therapeutics files to sell 14M shares of common stock
- Qualigen Therapeutics Board Experiences Key Changes
- Qualigen Therapeutics Announces Executive Shakeup and Board Revamp
- Qualigen Therapeutics appoints Kevin Richardson as Interim CEO and CFO
- Qualigen Therapeutics Granted Nasdaq Listing Extension
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue